A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Trebananib (Primary) ; Doxorubicin liposomal; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 11 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Sep 2015.